ASCO: A Week of Claims without cost data–Erbitux

This report from ASCO today illustrates the cancer PR train at full speed.

It reports that “The drug Erbitux lengthened the survival of patients with advanced lung cancer by about five weeks “(11.3 months survival vs 10.9 months) What’s not noted in the article is that this drug costs in the range of $10,000/month. Nowhere in the discussion is the question raised whether the drug is cost effective. What’s emphasized is that the drug is a step forward because there is a survival benefit–albeit very very short!

Powered by Zoundry

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s